地舒单抗在骨质疏松中的应用研究进展

Research Progress on the Application of Deshumazumab in Osteoporosis

在全球老龄化背景下,骨质疏松成为了一个公众健康问题。骨质疏松是一种骨稳态失衡的全身性骨疾病,地舒单抗作为首个核因子κB受体活化因子配体(receptor activator nuclear of factor kappa-B ligand, RANKL)抑制剂应用于骨质疏松治疗取得不错的疗效。虽然在中国2020年上市,但国外已有10余年的临床应用经验和大量的相关研究,可预见其在中国的应用也会越来越广泛。现将地舒单抗在骨质疏松中的应用及研究进展予以综述。

In the context of global aging, osteoporosis has become a public health problem. Osteoporosis is a systemic bone disease with bone homeostasis imbalance. As the first inhibitor of nuclear factor kappa B receptor activating factor ligand, deschumab has achieved good results in the treatment of osteoporosis. Although it is listed in China in 2020, it has more than 10 years of clinical application experience and a large number of related researches abroad, and it can be predicted that it will be more and more widely used in China. In this paper, the application and research progress of desuximab in osteoporosis are reviewed.